Absence of Anti-RBD Antibodies in SARS-CoV-2 Infected or Naive Individuals Prior to Vaccination with CoronaVac Leads to Short Protection of Only Four Months Duration.

Autor:	Oliveira CF; Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ananindeua 67030-000, PA, Brazil., Neto WFF; Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ananindeua 67030-000, PA, Brazil., Silva CPD; Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ananindeua 67030-000, PA, Brazil., Ribeiro ACS; Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ananindeua 67030-000, PA, Brazil., Martins LC; Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ananindeua 67030-000, PA, Brazil., Sousa AW; Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ananindeua 67030-000, PA, Brazil., Freitas MNO; Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ananindeua 67030-000, PA, Brazil., Chiang JO; Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ananindeua 67030-000, PA, Brazil., Silva FA; Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ananindeua 67030-000, PA, Brazil., Santos EBD; Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ananindeua 67030-000, PA, Brazil., Medeiros DBA; Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ananindeua 67030-000, PA, Brazil., Pinheiro GS; Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ananindeua 67030-000, PA, Brazil., Brandão GF; Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ananindeua 67030-000, PA, Brazil., Carvalho VL; Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ananindeua 67030-000, PA, Brazil., Azevedo RSS; Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ananindeua 67030-000, PA, Brazil., Vasconcelos PFC; Department of Biological and Health Sciences, University of Pará State, Belém 66087-670, PA, Brazil., Costa IB; Department of Virology, Evandro Chagas Institute, Ananindeua 67030-000, PA, Brazil., Costa IB; Department of Virology, Evandro Chagas Institute, Ananindeua 67030-000, PA, Brazil., Santos MCD; Department of Virology, Evandro Chagas Institute, Ananindeua 67030-000, PA, Brazil., Soares LS; Department of Virology, Evandro Chagas Institute, Ananindeua 67030-000, PA, Brazil., Bedran RLS; Department of Virology, Evandro Chagas Institute, Ananindeua 67030-000, PA, Brazil., Ferreira JL; Department of Virology, Evandro Chagas Institute, Ananindeua 67030-000, PA, Brazil., Amarilla AA; School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia., Modhiran N; School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia., McMillan CLD; School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia., Freney ME; School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia., Muller DA; School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia.; Australian Infectious Disease Research Centre, The University of Queensland, St Lucia, QLD 4072, Australia., Watterson D; School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia.; Australian Infectious Disease Research Centre, The University of Queensland, St Lucia, QLD 4072, Australia.; The Australian Institute for Biotechnology and Nanotechnology, The University of Queensland, St Lucia, QLD 4072, Australia., Casseb LMN; Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ananindeua 67030-000, PA, Brazil., Henriques DF; Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ananindeua 67030-000, PA, Brazil.
Jazyk:	angličtina
Zdroj:	Vaccines [Vaccines (Basel)] 2022 Apr 28; Vol. 10 (5). Date of Electronic Publication: 2022 Apr 28.
DOI:	10.3390/vaccines10050690
Abstrakt:	The COVID-19 pandemic is the biggest public health threat facing the world today. Multiple vaccines have been approved; however, the emergence of viral variants such as the recent Omicron raises the possibility of booster doses to achieve adequate protection. In Brazil, the CoronaVac (Sinovac, Beijing, China) vaccine was used; however, it is important to assess the immune response to this vaccine over time. This study aimed to monitor the anti-SARS-CoV-2 antibody responses in those immunized with CoronaVac and SARS-CoV-2 infected individuals. Samples were collected between August 2020 and August 2021. Within the vaccinated cohort, some individuals had a history of infection by SARS-CoV-2 prior to immunization, while others did not. We analyzed RBD-specific and neutralizing-antibodies. Anti-RBD antibodies were detected in both cohorts, with a peak between 45-90 days post infection or vaccination, followed by a steady decline over time. In those with a previous history of COVID-19, a higher, longer, more persistent response was observed. This trend was mirrored in the neutralization assays, where infection, followed by immunization, resulted in higher, longer lasting responses which were conditioned on the presence of levels of RBD antibodies right before the vaccination. This supports the necessity of booster doses of CoronaVac in due course to prevent serious disease.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu